Sovereign Infrastructure & Strategic Healthcare Partnerships

The UAE has done something few jurisdictions have attempted: treated advanced therapy as national infrastructure to be built rather than as a foreign product to be imported once approved elsewhere. That position makes it possible to place manufacturing, regulatory engagement, and clinical delivery in the same country, under the same authorities, on the same timeline.

The intent is durable domestic capability — trained local staff, resident manufacturing, and protocols that continue to run without external dependency — rather than a service delivered from outside and withdrawn when a contract ends.

Triple Helix Science operates across defined legal and clinical entities to ensure strict adherence to international GCP, GLP, and sovereign regulatory frameworks. Operating divisions across North America, Latin America, and the MENA region maintain localized compliance while adhering to a singular corporate quality standard.

Biopharmaceutical manufacturing in gene therapy is frequently outsourced to contract manufacturers with long lead times. Triple Helix Science maintains proprietary cleanroom suites for plasmid production, sterile filtration, and viral vector harvest to ensure direct quality control from nucleotide synthesis to clinical administration.

Clinical operations and surgical suites operate in partner hospitals across the Americas, Europe, the Middle East, and Asia, ensuring compliance with local pharmacopeia and regulatory jurisdictions.